Ruthbaby
- 06 May 2012 08:06

Sphere Medical has 141,757,872 Ordinary Shares of nominal value £0.01 each in issue.
The Wales Life Sciences Investment Fund 25,000,000 17.64%
Woodford Patient Capital Trust Plc 23,125,000 16.31%
LSP Life Sciences Fund 10,904,000 7.69%
Ortho-Clinical Diagnostics 8,141,250 5.74%
Fidelity Worldwide Investments 6,264,649 4.42%
Octopus Investments 6,250,000 4.41%
Ruffer LLP 5,653,895 3.99%
Royal London Asset Management 5,624,185 3.97%
Herald Investment Management 4,711,965 3.32%
Should be an exciting year ahead with developments.
Anybody had a look at this company?
Ruthbaby
- 04 Dec 2012 14:56
- 10 of 71
Have purchased another 400,000 shares to add to their holding..
Holding was 1,331,081 shares......
Now 1,799,363 shares......
Ruthbaby
- 01 Jul 2013 13:33
- 11 of 71
Looks a good tie up...
Ruthbaby
- 16 Oct 2013 14:30
- 12 of 71
Starting to create some attention and buying..at last......
Ruthbaby
- 17 Oct 2013 12:08
- 13 of 71
There is an awful lot of buying in those trades..even my trades are marked as sells?????
Ruthbaby
- 21 Oct 2013 15:02
- 14 of 71
Some blue coming through now...seller seems to have cleared....
Ruthbaby
- 22 Oct 2013 08:18
- 15 of 71
Shareprophet has tipped this stock recently....large seller has now cleared.......
Ruthbaby
- 17 Sep 2014 16:45
- 16 of 71
Got ce approval for Proxima device....Launching device tomorrow.....
Looks interesting now for a punt...imho....:-)
Ruthbaby
- 24 Apr 2015 07:34
- 17 of 71
Woodford's first fund investment.....
Proposed Placing and Open Offer
Cambridge, UK, 13 April 2015: Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, today announces that it is planning to raise, subject to certain conditions, approximately £12 million (before expenses), by way a Placing pursuant to which 75,000,000 New Ordinary Shares will be issued at 16 pence each to new and existing investors.
Woodford Investment Management, on behalf of its clients, has given a non-binding intent to invest up to £4 million in the Placing and the Wales Fund (being a fund raising up to £100 million focused on life sciences and managed by Arthurian), has given a conditional commitment to invest £4 million in the Placing. The Placing Shares have been conditionally placed by the Joint Brokers with new and existing institutional investors other than those which may be subscribed for by Woodford Investment Management, on behalf of its clients.
Could be finally turning a corner...
aldwickk
- 24 Apr 2015 07:59
- 18 of 71
You haven't added a EPIC to your thread
Ruthbaby
- 24 Apr 2015 10:04
- 19 of 71
Where do I do that or is it to late?
skinny
- 24 Apr 2015 10:07
- 20 of 71
It's not something that we mere mortals can do, but it may be worth asking Ian to do it on
this thread.
Ruthbaby
- 24 Apr 2015 10:30
- 21 of 71
Thank you guys!!
Ruthbaby
- 24 Apr 2015 14:48
- 22 of 71
Ah...still no epic....:-(
Ruthbaby
- 29 Apr 2015 08:06
- 23 of 71
29 April 2015
Sphere Medical Holding plc
Result of Open Offer
Cambridge, UK, 29 April 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announced on 13 April 2015 details of the Company's proposed fundraising through a Placing and Open Offer at 16 pence per share.
The last time and date for receipt of completed application forms and payment in full under the Open Offer was 11.00 a.m. on 28 April 2015. The Company announces that at that time that it had received valid acceptances in respect of 7,352,582 Open Offer Shares from Qualifying Shareholders with a value of some GBP1,176,413. This represents approximately 99% of the 7,425,661 Open Offer Shares offered. As a consequence, the Company has conditionally raised GBP13.2 million (before expenses) through the Placing and Open Offer.
The Placing and Open Offer are all subject to the approval of Shareholders at a General Meeting to be held at 10.00 a.m. on 30 April 2015.
Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 82,352,582 New Ordinary Shares to be issued pursuant to the Placing and Open Offer. It is expected that Admission will become effective on 1 May 2015. Following Admission, the Company will have 141,757,872 Ordinary Shares in issue.
The New Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares.
Commenting on today's announcement, Dr. Wolfgang Rencken, Chief Executive Officer of Sphere Medical, said:
"We are very appreciative of the continued support from a significant number of our long-term shareholders that have taken part in this Open Offer. The proceeds from the fundraising will further strengthen the Company's balance sheet as we accelerate the commercialisation of Proxima in Europe."
Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular dated 13 April 2015.
CC
- 28 May 2015 19:54
- 24 of 71
I have today bought a very small holding in this stock. It's not my typical type of play as I prefer stocks with a track record and something I can latch onto.
My rationale is as follows:
1. After a number of years the product is moving to the point of real sales. The market would appear to be huge but it is difficult to quantify how fast sales will increase. I suspect it will be slower than most would like but I am patient.
2. Neil Woodford took up £4m shares at 16p and if 16p is good enough for him I'm happy to take my chances at 16.8p
3. After the placing the shares inevitably fell but I am surprised they have come all the way back to the placing price. I guess someone took up the placing but didn't really want the shares and is selling the placing shares at a profit.
4. There is a daily flow of buys which sooner or later will soak up whoever is selling. Dont' be confused by the trade pattern - all those sells reported at 16.8p are buys.
5. The directors took part in the open offer and put their own money in.
black bird
- 29 May 2015 10:52
- 25 of 71
diagnostic devices , have a poor track record, buy after the next loss a/c 12pence ?
Ruthbaby
- 31 May 2015 21:26
- 26 of 71
16.80p have all been buys as I have added but it was marked down as red....
No issues as I believe this will move quickly when it turns....
Ruthbaby
- 01 Jun 2015 15:30
- 27 of 71
RNS...
Sphere Medical confirms that its Annual General Meeting will be held at 11.00am on Thursday, 25 June 2015 at Harston Mill, Harston, Cambridge CB22 7GG. The Notice of Annual General Meeting is set out in the Annual Report and Accounts.
Ruthbaby
- 01 Jun 2015 15:31
- 28 of 71
RNS...
Sphere Medical confirms that its Annual General Meeting will be held at 11.00am on Thursday, 25 June 2015 at Harston Mill, Harston, Cambridge CB22 7GG. The Notice of Annual General Meeting is set out in the Annual Report and Accounts.
Ruthbaby
- 25 Jun 2015 07:32
- 29 of 71
First Sales and Appointment of New Chairman
Cambridge, UK, 25 June 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that, at its Annual General Meeting, which will take place at 11:00 am today at Harston Mill, Harston, Cambridge, Dr Anthony Martin, Non-Executive Chairman, will provide the following update:
The two major objectives for Sphere Medical since the beginning of the year have been: the continued commercialisation of Proxima 3 into the UK market and more latterly, into the German, Dutch and Belgium markets; and the finalisation of the development of Proxima 4 alongside Ortho-Clinical Diagnostics as well as fulfilling our obligations under the Collaboration Agreement.
I am pleased to report that the Company has delivered its first commercial order of Proxima 3 product, which represents an important milestone for the Company. Furthermore, we are continuing to grow the number of hospitals showing interest in Proxima 3 and work is continuing with these hospitals for the sale of Proxima into their intensive care settings. The evaluations Sphere has undertaken this year within hospitals have shown that Proxima can reduce the time from ordering a blood gas test to receiving the result by 40% to 60% in a typical clinical environment as well as eliminating the time the nurse is required to spend away from the patient.
Under the terms of the Collaboration Agreement with Ortho-Clinical Diagnostics, Sphere Medical has granted an option to Ortho-Clinical Diagnostics to enter into good faith negotiations for the exclusive rights to commercialise Proxima 4. In connection with this option, Sphere Medical has certain obligations to compile and deliver a data package of reports detailing key product attributes and commercial observations related to Proxima 3 and Proxima 4. Sphere Medical is on schedule to deliver all of these reports.
Work is also on schedule for the submission of the technical and design dossier files necessary for the approval of Proxima 4's CE marks. We currently expect to release these files to our Notified Body during Q3 2015.
On 30 April we announced a successful £13.2 million (gross of costs) fundraise from new and existing shareholders to further strengthen the Company's balance sheet and to enable the achievement of near-term operational and commercial value drivers which we are confident will create substantial value for our shareholders.
On 7 January we announced David Martyr's and Meinhard Schmidt's appointments to the Board as Non-Executive Directors. I indicated at that time that I would be reviewing our succession plan for the Chairmanship of Sphere Medical. I have been Chairman of Sphere Medical for ten years and over that time the Company has developed from a private company engaged in research and development to a commercially-focused public company selling its CE-marked medical device into Europe. I now believe it is time to for me to stand down from my role and therefore I am very pleased to announce that David has agreed to replace me as Chairman. I have every confidence that David's extensive experience within the medical device industry will be of significant benefit to Sphere Medical in the coming years.